By 2030, we aim to launch at least 20 new medicines and achieve $80 billion in Total Revenue, with sustained growth thereafter.
Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca
We have
projects in our pipeline
Transforming the Future of Chronic Disease Care
What science can do storiesBy 2030, we aim to launch at least 20 new medicines and achieve $80 billion in Total Revenue, with sustained growth thereafter.
Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca
We have
projects in our pipeline